N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

July 31, 2006

Conditions
DiarrheaDrug/Agent Toxicity by Tissue/OrganNeuroblastoma
Interventions
DRUG

cefixime

DRUG

irinotecan hydrochloride

DRUG

temozolomide

Trial Locations (13)

19104

Children's Hospital of Philadelphia, Philadelphia

30322

AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, Atlanta

60614

Children's Memorial Hospital - Chicago, Chicago

94143

UCSF Comprehensive Cancer Center, San Francisco

94304

Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto

98105

Children's Hospital and Regional Medical Center - Seattle, Seattle

90027-0700

Children's Hospital Los Angeles, Los Angeles

46202-5289

Indiana University Cancer Center, Indianapolis

02115

Children's Hospital Boston, Boston

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston

48109-0718

University of Michigan Comprehensive Cancer Center, Ann Arbor

45229-3039

Cincinnati Children's Hospital Medical Center, Cincinnati

77030-2399

Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Children's Hospital Los Angeles

OTHER

NCT00093353 - N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma | Biotech Hunter | Biotech Hunter